Showing 1 - 10 of 17
Persistent link: https://www.econbiz.de/10015100980
Persistent link: https://www.econbiz.de/10001860156
The pricing of medical products and services in the U.S. is notoriously complex. In health care, supply prices (those received by the manufacturer) are distinct from demand prices (those paid by the patient) due to health insurance. The insurer, in designing the benefit, decides what prices...
Persistent link: https://www.econbiz.de/10012461776
After receiving FDA approval, a generic drug manufacturer can launch "at risk" before conclusion of any patent infringement litigation, but it risks paying damages if it loses. The generic can eliminate the risk by waiting to launch until the appeals process is complete but waiting has downsides...
Persistent link: https://www.econbiz.de/10012616579
Settlements of drug patent disputes that involve a potential payment from the brand to the generic signal a possible collusive profit split with a threat to competition, and have undergone intensive scrutiny in the literature on law and economics. A common feature of these brand-generic...
Persistent link: https://www.econbiz.de/10012938770
The pricing of medical products and services in the U.S. is notoriously complex. In health care, supply prices (those received by the manufacturer) are distinct from demand prices (those paid by the patient) due to health insurance. The insurer, in designing the benefit, decides what prices...
Persistent link: https://www.econbiz.de/10013128277
Persistent link: https://www.econbiz.de/10003387041
Persistent link: https://www.econbiz.de/10002886886
Persistent link: https://www.econbiz.de/10014226019
Drug patent litigation settlements containing brand-to-generic "reverse payments" are a decades old antitrust concern that has been estimated to cost drug purchasers billions of dollars per year. Most estimates of the harm rely on the Federal Trade Commission's calculation that such payments...
Persistent link: https://www.econbiz.de/10015145147